高盛:升德琪医药-B(06996.HK)目标价至2.99港元 ATG-022竞争力加强

智通财经
Aug 22
【高盛:升德琪医药-B(06996.HK)目标价至2.99港元 ATG-022竞争力加强】智通财经APP获悉,高盛发布研报称,德琪医药-B(06996.HK)在不可切除或转移性胃癌(GC)方面的二期数据更新令人鼓舞,公司旗下ATG-022获国家药监局药品审评中心授予突破性治疗药物认定,用于两种治疗的CLDN18.2阳性、HER2阴性不可切除或转移性胃癌或胃食管结合部腺癌(GC/GEJ)患者。高盛将德琪医药目标价由2.61港元上调至2.99港元,以反映ATG-022在治疗胃癌方面的竞争地位增强,导致未来几年的销售预测上升。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10